Avalon GloboCare Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Avalon GloboCare Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 12, 2025 | $0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2024 | $1.33M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $1.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.20M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.39M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.38M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.55M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.56M | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | $1.08M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $616.4K | Mar 13, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $272.7K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $414.5K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $390.2K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $339.9K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $388.0K | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | $49.8K | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($543.4K) | Mar 13, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.26M) | Mar 30, 2026 |
| FY2025 | Dec 12, 2025 | $94.5K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($7.90M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($16.71M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($11.93M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($9.09M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($12.68M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($18.07M) | Mar 30, 2021 |
| FY2019 | Sep 30, 2019 | ($5.38M) | Apr 6, 2020 |
| FY2019 | Dec 31, 2018 | ($8.05M) | Apr 6, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.59M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($4.84M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($15.75M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($8.79M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($8.83M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($12.45M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($19.38M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($7.63M) | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | ($3.88M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $76.9K | Mar 13, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $109.6K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $731.3K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.03M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $883.9K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.78M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $39.1K | Apr 6, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.97M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($6.50M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.04M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($5.02M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($7.55M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($7.08M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($4.40M) | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | ($1.34M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $14.0K | Mar 13, 2018 |
| FY2015 | Dec 31, 2015 | ($30.1K) | Feb 24, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $22.2K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.7K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $17.5K | Mar 30, 2023 |
| FY2018 | Dec 31, 2017 | $148.0K | Mar 26, 2019 |
| FY2016 | Dec 31, 2016 | $334 | Mar 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.40M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $20.99M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $20.58M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $19.75M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $10.24M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $10.37M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $10.49M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $13.40M | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | $12.67M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $3.71M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.17M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $13.88M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $13.21M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.59M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $7.16M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.25M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $6.03M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $2.14M | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | $5.36M | Mar 26, 2019 |
| FY2015 | Dec 31, 2015 | $5.6K | Feb 24, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.23M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $7.10M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.37M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.16M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.08M | Mar 30, 2023 |
| FY2022 | Dec 31, 2020 | $4.12M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $4.47M | Mar 30, 2022 |
| FY2019 | Sep 30, 2019 | $5.75M | Apr 6, 2020 |
| FY2020 | Dec 31, 2018 | $11.25M | Mar 30, 2021 |
| FY2018 | Dec 31, 2017 | $7.89M | Mar 26, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.81M | Mar 30, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($105.93M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($87.67M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($79.77M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($63.06M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($51.13M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($42.04M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($29.36M) | Mar 30, 2021 |
| FY2019 | Sep 30, 2019 | ($25.43M) | Apr 6, 2020 |
| FY2019 | Dec 31, 2018 | ($11.29M) | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | ($3.52M) | Mar 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.1K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.66M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $285.4K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.99M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $807.5K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $726.6K | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $764.9K | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $2.25M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $3.03M | Apr 6, 2020 |
| FY2018 | Dec 31, 2016 | $2.89M | Mar 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $3.00M | Mar 30, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.45M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 1.44M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 733,302 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 9.96M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 8.85M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 82.28M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 76.21M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 73.31M | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | 70.28M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | 61.63M | Mar 13, 2018 |